TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 358427
Drug: Carbuterol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbuterol (2.0 mg tablets)
Study: 358427
Drug: Fenoterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (2.5 mg tablets)
Study: 358427
Drug: Hexoprenaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (1 mg tablets)
Study: 358427
Drug: Carbuterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbuterol (200 mg aerosol)
Study: 358427
Drug: Fenoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (400 mg aerosol)
Study: 358427
Drug: Hexoprenaline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (200 mg aerosol)
Study: 25668261
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate (37.5 mg of elemental iron) daily for 24 weeks (168 days)
Study: 7717236
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.6 mg/kg
Study: 19414968
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.6 mg/kg plus nitrous oxide-oxygen inhalation
Study: 15897444
Drug: Antithrombotic agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic agents alone
Study: 7617495
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel and foam
Study: 2533187
Drug: COP 1
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COP 1 treatment
Study: 31174403
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 1000 mg calcium and 800 IU cholecalciferol
Study: 31174403
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 1000 mg calcium and 800 IU cholecalciferol with an additional 1 ml liquid cholecalciferol (50,000 IU) monthly
Study: 23588240
Drug: True-elimination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: True-elimination diet + topical nifedipine and lidocaine
Study: 23588240
Drug: Sham-elimination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-elimination diet + topical nifedipine and lidocaine
Study: 21439030
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (n = 16)
Study: 20133266
Drug: fosamprenavir/ritonavir 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosamprenavir/ritonavir 1400 mg/100 mg once daily
Study: 20133266
Drug: fosamprenavir/ritonavir 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosamprenavir/ritonavir 700 mg/100 mg twice daily
Study: 10360370
Drug: Idarubicin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin (8 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Study: 10360370
Drug: Mitoxantrone (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (7 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Study: 10360370
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg/day) following induction
Study: 10360370
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF following induction
Study: 8706174
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Chongqing Glaxo Limited (Group A)
Study: 8706174
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Glaxo UK (Group B)
Study: 6122463
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg slow release oxprenolol
Study: 6122463
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide
Study: 30943910
Drug: Antenatal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroids (betamethasone 12 mg, 3 mL intramuscularly)
Study: 30943910
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 3 mL IM)
Study: 26926544
Drug: Surgical section
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical section of the filum plus medical treatment
Study: 18973910
Drug: Combined stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined stimulating surface projection zone of decussation of pyramid and traditional acupuncture treatment
Study: 18973910
Drug: Traditional acupuncture
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional acupuncture treatment only
Study: 15527071
Drug: Fructose administration
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose administration
Study: 31870702
Drug: Sucrose administration
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose administration
Study: 30075491
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg oral tablets
Study: 17892999
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (3 glasses daily for 6 months)
Study: 17892999
Drug: Water (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control group, 3 glasses daily for 6 months)
Study: 14706203
Drug: Propofol treatment
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol treatment
Study: 31313547
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg once daily for 4 months along with erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis
Study: 31313547
Drug: Erythropoietin 6000
Normalized name: ERYTHROPOIETIN
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis without atorvastatin for 4 months
Study: 27928454
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate supplementation (interdialytic doses)
Study: 27928454
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral sodium bicarbonate supplementation, higher bicarbonate prescriptions in dialysis)
Study: 27965790
Drug: Intradialytic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic oral nutritional supplement (ONS)
Study: 20384749
Drug: Low-fluence Q-switched
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluence Q-switched Nd:YAG laser after 8 weeks of topical TC treatment
Study: 20384749
Drug: Topical triple
Normalized name: Triple Paste Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triple combination (TC) cream
Study: 17941095
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) psychoeducational workshop
Study: 12590619
Drug: Sedating antidepressants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedating antidepressants (amitriptyline, imipramine, doxepin, mianserin)
Study: 12590619
Drug: Nocturnal doses
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal doses of sedating antidepressants (dothiepin, mianserin, mirtazapine)
Study: 12590619
Drug: Nonsedating antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsedating antidepressants (moclobemide, fluoxetine, paroxetine, venlafaxine, nefazodone)
Study: 12590619
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of nonsedating antidepressants and benzodiazepines
Study: 12590619
Drug: Antidepressants in
Normalized name: Other antidepressants in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants in clinical trials
Study: 10683095
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink (0.8 g x kg(‐1) body weight of glucose)
Study: 10683095
Drug: Glutamine drink
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of glutamine)
Study: 10683095
Drug: Wheat hydrolysate
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of wheat hydrolysate)
Study: 10683095
Drug: Whey hydrolysate
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of whey hydrolysate)
Study: 8692117
Drug: Bolus 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 5‐FU 600 mg/m2 plus folinic acid 300 mg/m2 day 2 to 4 with or without dipyridamole 3 x 75 mg p.o. day 1 to 5
Study: 8692117
Drug: Bolus 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 5‐FU 300 to 350 mg/m2, folinic acid 200 mg/m2 and interferon 5 x 10(9) U/m2 s.c. day 1 to 5
Study: 8692117
Drug: PALA 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA 250 mg/m2, MTX 250 mg/m2 day 1 and bolus FU 600 mg/m2 day 2 q day 14
Study: 8692117
Drug: FU 2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU 2.6 g/m2 given as 24‐h infusion plus interferon 3 x 10(9) Ul s.c.
Study: 8692117
Drug: FU 2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU 2.6 g/m2 given as 24‐h infusion, folinic acid 500 mg/m2 as 2‐h infusion with or without interferon 3 x 10(9) U s.c.
Study: 8692117
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion regimens
Study: 1531467
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional drugs after general anesthesia (controls)
Study: 23281758
Drug: L-threonine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine supplementation at 0.2%
Study: 23281758
Drug: L-threonine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine supplementation at 0.3%
Study: 23281758
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0% L-threonine)
Study: 19624730
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream with Bifidobacterium longum lysate at 10% (n = 33)
Study: 19624730
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (n = 33)
Study: 19624730
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream with Bifidobacterium longum lysate at 10%
Study: 11378052
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) at doses of 300 mg, 600 mg, and 900 mg daily
Study: 18370544
Drug: Atenolol 50mg
Normalized name: ATENOLOL 50MG TAB
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 50mg daily
Study: 18370544
Drug: Perindopril 4mg
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril 4mg daily
Study: 18211932
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 400 mg
Study: 8157551
Drug: Intravenous ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ofloxacin 400 mg
Study: 3410937
Drug: GH (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.15 U/kg, sc, three times weekly)
Study: 3410937
Drug: GH (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.09 U/kg, three times weekly)
Study: 3410937
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with EE2 (50 ng/kg.day) and GH (0.09 U/kg, three times weekly)
Study: 3410937
Drug: GH (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.15 U/kg, three times weekly) with EE2 (100 ng/kg.day)
Study: 29071946
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus western medicine
Study: 29071946
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine only (Control)
Study: 21983111
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and Aspirin (C+A)
Study: 17599602
Drug: Recombinant nematode
Normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant nematode anticoagulant protein c2 (rNAPc2) administered intravenously every 48 hours for a total of 1 to 3 doses (1.5 to 10 microg/kg)
Study: 17599602
Drug: Higher-dose rNAPc2
Normalized name: rNAPc2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose rNAPc2 (≥7.5 microg/kg)
Study: 17599602
Drug: Half-dose UFH
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose UFH
Study: 2150640
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 to 5.0mg twice daily
Study: 2150640
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 to 25mg twice daily
Study: 28627376
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler with AeroChamber‐MV (MDI‐AC)
Study: 22075163
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Grief Therapy (FFGT) Model
Study: 15347773
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (600 mg twice daily for 3 months)
Study: 31111045
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative anti-inflammatory treatment (Cohort I)
Study: 31111045
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment (warming compress, lid hygiene, and anti-inflammatory treatment) and routine postoperative anti-inflammatory treatment (Cohort II)
Study: 31111045
Drug: Enhanced postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced postoperative anti-inflammatory treatment (Cohort III)
Study: 15156004
Drug: Clopidogrel pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel pre-treatment (75 mg x 2 daily at least 48 hours before intervention)
Study: 15156004
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose (300 mg at intervention time)
Study: 31596061
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine with a loading dose of 1 μg/kg body weight followed by 0.2 μg/kg body weight/hour via continuous infusion
Study: 31596061
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 2 mg/kg body weight with atropine 0.01 mg/kg body weight
Study: 28129985
Drug: Pitolisant (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant (5 mg, 10 mg, 20 mg, or 40 mg once daily)
Study: 23884072
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with pegylated interferon (peg‐IFN) alfa‐2a plus self‐administered ribavirin (RBV)
Study: 23884072
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with pegylated interferon (peg‐IFN) alfa‐2a plus self‐administered ribavirin (RBV)
Study: 23884072
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (among those who received it)
Study: 23884072
Drug: Overall participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall participants who received at least 1 dose of study medication
Study: 20506504
Drug: Colposcopically directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colposcopically directed biopsies taken within 6 months of definitive therapy
Study: 19434697
Drug: Stapler combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stapler combined with seromuscular patch
Study: 16479752
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded tapered implants with single provisional crowns at surgery and definitive crowns 8 weeks later
Study: 16479752
Drug: Conventional 2-stage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 2-stage implants
Study: 1526265
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram of alphacalcidol daily for 4 months
Study: 3903813
Drug: Open drug
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open drug (DL-phenylalanine)
Study: 3903813
Drug: L-phenylalanine
Normalized name: L-Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine
Study: 29132842
Drug: 3.3% glucose/saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3% glucose/saline (51mEq/L sodium and 33g/L glucose)
Study: 29132842
Drug: 5% glucose/saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose/saline (154mEq/L sodium and 50g/L glucose)
Study: 24868587
Drug: Interdisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary treatment (experimental group)
Study: 24868587
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological therapy (control group)
Study: 12358339
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) only (group C)
Study: 7863760
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime (3 g infused in 15-25 min in preliminary study, 3 g infused in 15 min in main study)
Study: 1778193
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg twice a day
Study: 3691593
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg daily
Study: 31529663
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of autologous bone marrow mononuclear cells (MNCs) at a target dose of 10 million cells per kilogram, administered within 24-72 hours of stroke onset.
Study: 31529663
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of autologous bone marrow mononuclear cells (MNCs)
Study: 26373634
Drug: Mindfulness Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness Based Cognitive Therapy (MBCT) in addition to treatment as usual (TAU)
Study: 21242584
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (IMQ) once daily, 5 days/week for 6 weeks
Study: 19568709
Drug: Rhodiola-Gingko Capsule
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola-Gingko Capsule (RGC), 270 mg herbal extracts, 4 capsules per day for 7 weeks
Study: 17353578
Drug: Regular red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular red wine (250 ml)
Study: 17353578
Drug: Dealcoholized red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dealcoholized red wine (250 ml)
Study: 14753131
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy in routine clinical practice (RCP)
Study: 11491635
Drug: Penicillin (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (28 capsules of 500 mg taken every 6 hours for 7 days)
Study: 16809258
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia (EDA) with ropivacaine + paracetamol (4 x 1 g tablet) + injected or oral morphine on demand
Study: 16809258
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone hydrochloride (2 x 10 mg tablet) + paracetamol (4 x 1 g tablet) + injected or oral morphine on demand
Study: 10566625
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/day for 3 months)
Study: 6688799
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg per os daily for 6 months
Study: 6688799
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg per os daily for 6 months
Study: 6688799
Drug: Topical antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antacids as needed for 6 months
Study: 29383606
Drug: Indigo carmine
Normalized name: indigo carmine
DrugBank: Indigotindisulfonic acid (DB11577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indigo carmine mixed solution
Study: 27378823
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg bid 24 h prior to ascent
Study: 20193645
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 to 50 mg